[1] JIN FY, LIANG GY, ZHANG Z, et al.Studies on the quality standard for Xianling Gubao capsule[J]. Chin Pharm J(中国药学杂志), 2002, 37(5): 54-57. [2] National Medical Products Administration. National Medical Products Administration has drawn attention to the drug risks of Xianling Gubao oral preparation[EB/OL]. (2016-12-08)[2023-03-26]. https://www.nmpa.gov.cn/directory/web/nmpa/xxgk/yjjsh/ypblfytb/20161208170501622.html. [3] Drug induced Liver Disease Study Group, Chinese society of Hepatology, Chinese Medical Association. Guidelines for the management of drug-induced liver injury[J]. J Clin Hepatol(临床肝胆病杂志), 2015, 31(11): 1752-1769. [4] PENG SY, XIE YM, WANG ZF, et al.Analysis of adverse reactions of Xianling Gubao preparation based on real world SRS data[J]. China J Chin Mater Med(中国中药杂志), 2020, 45(10): 2316-2321. [5] WANG ZF, PENG SY, XIE YM, et al.Real world multi-dimensional design of clinical safety research on Xianling Gubao preparation[J]. World Chin Med(世界中医药), 2020, 15(1): 7-12. [6] YANG YH, ZHOU YL.Liver dysfunction resulting from Xianlinggubao capsules in 2 cases[J]. Adv Drug React J(药物不良反应杂志), 2007, 9(3): 214-215. [7] LI S, WANG XJ, ZHUANG W, et al.Analysis of 39 cases of adverse reactions/events in Xianling Gubao capsules[J]. China Pharmacist(中国药师), 2019, 22(6): 1068-1071. [8] GUO ZJ, LI P, KANG QJ, et al.Safety analysis and consideration on hepatotoxicity of Psoralea corylifolia L.[J]. China Journal of Traditional Chinese Medicine and Pharmacy(中华中医药杂志), 2022, 37(5): 2616-2621. [9] QIN ZF, YAO ZH, DAI Y, et al.HPLC-MS/MS analysis of the absorbed components in serum after intragastric administration of Xianlinggubao to rats[J]. J Instrumental Anal(分析测试学报), 2013, 32(4): 420-426. [10] LIN HW, JIANG HX, LU WS, et al.Study on hepatotoxicity of Xianling Gubao extract and its unilateral extracts[J]. Pharm Care Res(药学服务与研究), 2020, 20(2): 98-101. [11] HUANG Y, LIU YL, MA RY, et al.Clinical case analysis and disassembled prescription study of liver injury related to Xianling Gubao[J]. Acta Pharm Sin(药学学报), 2021, 56(1): 266-273. [12] GUO ZJ, ZHANG JX, KANG QJ, et al.Comparative study on hepatotoxicity of Psoraleae Fructus in rats and mice[J]. Chin J Exp Tradit Med Formul(中国实验方剂学杂志), 2020, 26(22): 16-25. [13] YANG C, YAO C.Clinical analysis and treatment of 10 cases of liver injury caused by Xianlinggubao capsule[J]. Anti Infect Pharm(抗感染药学), 2021, 18(9): 1366-1369. [14] WANG Y, ZHANG H, JIANG JM, et al.Hepatotoxicity induced by psoralen and isopsoralen from Fructus Psoraleae: Wistar rats are more vulnerable than ICR mice[J]. Food Chem Toxicol, 2019, 125: 133-140. [15] ZHANG Y, BI YN, YUAN XM, et al.Study on hepatotoxic components of Psoraleae Fructus based on target organs[J]. Lishizhen Med Mater Med Res(时珍国医国药), 2017, 28(8): 1844-1847. [16] HUANG JY, WANG Q, BI YN, et al.Effect of isopsoralen on hepatic function and bile acid transporters in SD rats with different administration periods[J]. Chin Pharmacol Bull(中国药理学通报), 2019, 35(2): 260-264. [17] ZHONG YH, SHEN GL, YUAN M, et al.Evaluation of cytochrome P450 inhibition and induction by psoralen and isopsoralen in vitro[J]. Chin J Pharmacol Toxicol(中国药理学与毒理学杂志), 2012, 26(4): 522-528. [18] ZHOU K, WANG AH, CHAI LJ, et al.Cytotoxicity of bakuchiol on HepG2 cells and effects of BSEP, NTCP, FXR, CYP7A1[J]. J Toxicol(毒理学杂志), 2015, 29(3): 193-196. [19] HU XJ, ZHANG YB, ZHAO ZJ, et al.Metabolic detoxification of bakuchiol is mediated by oxidation of CYP 450s in liver microsomes[J]. Food Chem Toxicol, 2018, 111: 385-392. [20] GUO ZJ.Study on drug factors, toxicity mechanism and material basis of Psoraleae Fructus hepatotoxicity[D]. Beijing: Beijing University of Traditional Chinese Medicine, 2021. [21] GUO ZJ, LI P, WANG CG, et al.Five constituents contributed to the Psoraleae Fructus-induced hepatotoxicity via mitochondrial dysfunction and apoptosis[J]. Front Pharmacol, 2021, 12: 682823. [22] ZHOU K, BI YN, SHI H.Psoralen induced bile acid accumulation and cytotoxicity by inhibiting MRP2 and MRP3 in HepG2 cells[J]. Chin Pharmacol Bull(中国药理学通报), 2015, 31(8): 1112-1116. [23] ZHANG XJ, CAO HQ, XING ZH, et al.Effects of Psoralea corylifolia L. on hepatocyte morphology, liver function and mitochondrial membrane potential in mice[J]. Chin Tradit Patent Med(中成药), 2014, 36(1): 160-162. [24] ZHANG Y, LI J, CHEN Y, et al.The role of hepatic antioxidant capacity and hepatobiliary transporter in liver injury induced by isopsoralen in zebrafish larvae[J]. Hum Exp Toxicol, 2018, 1(9): 1-9. [25] WANG D, JIA DX, LI ZZ, et al.Discussion on safety evaluation and risk control measures of Epimedii Folium[J]. China J Chin Mater Med(中国中药杂志), 2019, 44(8): 1715. [26] ZHANG L, ZHANG JX, FAN QY, et al.Hepatoxicity of epimedii folium in rat model based on uniform design and regression analysis[J]. Chin J Exp Tradit Med Formul(中国实验方剂学杂志), 2018, 24(6): 189-197. [27] WANG ZL.Susceptible components and mechanism studies of Epimedii Folium-induced immunological idiosyncratic liver injury based on NLRP3 inflammasome[D]. Chengdu: Chengdu University of Traditional Chinese Medicine, 2021. [28] GAO Y, WANG ZL, TANG JF, et al.New incompatible pair of TCM: Epimedii Folium combined with Psoraleae Fructus induces idiosyncratic hepatotoxicity under immunological stress conditions[J]. Front Med, 2020, 14: 68-80. [29] CHENG JH, CAI HD.Adverse reactions to Zhuangguguanjie Wan and cause analysis[J]. Adv Drug React J(药物不良反应杂志), 2000, 1(1): 15-19. [30] ZHU CW, WANG HN, ZHANG YL, et al.Liver injury caused by Xianlinggubao capsules[J]. Chin Hepatol(肝脏), 2018, 23(12): 1090-1093. [31] YANG K.Sex difference characteristics and serum metabonomics study of liver injury in rats caused by psoralen and isopsoralen[D]. Nanchang: Jiangxi University of Traditional Chinese Medicine, 2021. [32] ZHAO XW, XU CL.Hepatic injury and hepatitis B virus reactivation due to concomitant use of Xianlinggubao capsules and omeprazole[J]. Adv Drug React J(药物不良反应杂志), 2012, 14(1): 60-61. [33] ZHENG MJ, ZHOU Y, LYU XQ.Xianlinggubao capsules combined with diclofenac sodium sustained-release capsules to cause liver failure: a case report[J]. Chinese Journel of Pharmacovigilance(中国药物警戒), 2014, 11(8): 507-508. [34] GUO ZJ, ZHANG JX, TU C, et al.Thoughts on several issues of potential hepatotoxicity in Chinese medicines[J]. China Journal of Traditional Chinese Medicine and Pharmacy(中华中医药杂志), 2020, 35(11): 5399-5402. [35] CAO SS, GONG S, YAN M, et al.Preventive effects of Danshen on cisplatin-induced hepatotoxicity[J]. Chin Pharmacol Bull(中国药理学通报), 2017, 33(1): 144-145. [36] LU S, GUO JL, BIAO YN, et al.Effect of Danshen and Zexie on lipid metabolism and PPARα gene expression[J]. J Hebei Tradit Chin Med Pharmacol(河北中医药学报), 2022, 37(2): 45-48. [37] ZHANG YF, CHEN L.The study of liver toxicity protective effects of tanshinone ⅡA to isoniazid and rifampicin in mice[J]. Henan J Prev Med(河南预防医学杂志), 2011, 22(5): 399-400. [38] CHEN ZY, HUANG JS, XU YJ, et al.TanshinoneⅡa alleviates acute liver and kidney injury in septic rats[J]. Chin J Immunol(中国免疫学杂志), 2020, 36(13): 1578-1582. [39] WANG WL, JYU DH, LIU MJ, et al.Research progress on pharmacology of effective components of dipsacales[J]. Chin J Med Guide(中国医药导刊), 2015, 17(10): 1059-1060. [40] SONG D, CHEN SS, LI PY, et al.Attenuating the potential hepato-toxicity of Psoraleae Fructus by pre-processing: the alcohol soaking and water rinsing method[J]. Acta Pharm Sin(药学学报), 2020, 55(2): 276-282. [41] HONG L, WANG Z, TANG XH, et al.Processing of psoraleae fructus based on combination of Leigong method and salt processed method and its hepatotoxicity evaluation[J]. Chin Tradit Herb Drugs(中草药), 2021, 52(22): 6983-6989. |